Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 3/20 | 0.41 |
| ▸ | RXRB | P28702 | 3/20 | 0.41 |
| ▸ | RXRG | P48443 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.38 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989899 | 0.89 | CYP1A2 (0.58) | CYP1A2CYP2D6CYP2C19RXRARXRB | |
| SCHEMBL16016128 | 0.86 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19RXRARXRB | |
| SCHEMBL2993679 | 0.85 | PLA2G10 (0.48) | CYP1A2CYP2D6CYP2C19PLA2G4A | |
| SCHEMBL2984035 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP2C19RXRARXRB | |
| SCHEMBL2984870 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP2C19RXRARXRB | |
| SCHEMBL3000671 | 0.83 | EDNRA (0.48) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4148824 | 0.82 | EGFR (0.46) | CYP1A2CYP2C19 | |
| SCHEMBL3105826 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2D6CYP2C19RXRARXRB | |
| SCHEMBL2997524 | 0.82 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP2C19RXRARXRB | |
| SCHEMBL2991027 | 0.81 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP2C19RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | claimed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | CYP1A2 3478/4885CYP2D6 1199/4885CYP2C19 4084/4885 |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | CYP1A2 3478/4885CYP2D6 1199/4885CYP2C19 4084/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | CYP1A2 1842/4885CYP2D6 305/4885CYP2C19 2450/4885 |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | PSEN2, PSEN1, CLN6 | CYP1A2 2251/4885CYP2D6 479/4885CYP2C19 3498/4885 |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | PSEN2, CHAT, PSEN1 | CYP1A2 2194/4885CYP2D6 1089/4885CYP2C19 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.